{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["English JD"],"funding":["NHLBI NIH HHS","University of Michigan Office of the Provost MCube3.0"],"pagination":["10742484221140303"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9841513"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27"],"pubmed_abstract":["<h4>Background</h4>Despite advances in treatments, myocardial infarction (MI) remains a significant cause of morbidity and mortality worldwide. Our team has previously shown that valproic acid (VPA) is cardio-protective when administered to rats post-MI. The aim of this study was to investigate the association of VPA use with post-MI heart failure (HF) development in humans.<h4>Methods</h4>This study was a random effects meta-analysis of two retrospective case-control studies collected from electronic health record (Michigan Medicine) and claims data (OptumInsight). Cases with an active prescription for VPA at the time of their MI were matched 1:4 to controls not taking VPA at the time of their MI by multiple demographic and clinical characteristics. The primary outcome, time-to-HF develop"],"journal":["Journal of cardiovascular pharmacology and therapeutics"],"pubmed_title":["Association of Valproic Acid Use With Post-Myocardial Infarction Heart Failure Development: A Meta-Analysis of Two Retrospective Case-Control Studies."],"pmcid":["PMC9841513"],"funding_grant_id":["K08 HL146990","R01 HL163672","U064172","R01 HL139735"],"pubmed_authors":["English JD","Tian S","Luzum JA","Wang Z"],"additional_accession":[]},"is_claimable":false,"name":"Association of Valproic Acid Use With Post-Myocardial Infarction Heart Failure Development: A Meta-Analysis of Two Retrospective Case-Control Studies.","description":"<h4>Background</h4>Despite advances in treatments, myocardial infarction (MI) remains a significant cause of morbidity and mortality worldwide. Our team has previously shown that valproic acid (VPA) is cardio-protective when administered to rats post-MI. The aim of this study was to investigate the association of VPA use with post-MI heart failure (HF) development in humans.<h4>Methods</h4>This study was a random effects meta-analysis of two retrospective case-control studies collected from electronic health record (Michigan Medicine) and claims data (OptumInsight). Cases with an active prescription for VPA at the time of their MI were matched 1:4 to controls not taking VPA at the time of their MI by multiple demographic and clinical characteristics. The primary outcome, time-to-HF develop","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan-Dec","modification":"2025-04-04T00:02:55.177Z","creation":"2025-04-04T00:02:55.177Z"},"accession":"S-EPMC9841513","cross_references":{"pubmed":["36416392"],"doi":["10.1177/10742484221140303"]}}